GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Miguel Attard appointed CEO of Gemini Malta
'After 15 years in traditional finance the opportunity presented itself at the right time to transition into the crypto and ...
MAKA CEO on why brands shouldn’t rush into AI-led advertising
'Audiences can smell when something’s off.'
Casa Rooms Director: Proposed short-let rules ‘lack the teeth’ to work
Cecil McCarthy reacts to the newly tabled regulations for short-term and long-term rentals.
67m Benetti superyacht spotted in Malta’s Grand Harbour
The yacht cruises comfortably at 12 knots and can reach speeds of up to 16 knots.
